Jul. 2006	Establishment of MediBIC (Subsidiary of MediBIC Group) as a result of corporate division.
Jul. 2006	MediBIC shifts to a holding company and changes its name to MediBIC Group.
Jun. 2006	MediBIC and Lipomics starts business collaboration on Lipid Metabolism Analysis Service.
May 2006	Kansai branch changes its name to Kansai Laboratory.
Apr. 2006	Launch sales promotion of ArrayAssist®-4 (Gene Expression Analysis Software) and starting data analysis business of ArrayAssist which its basic technology originally developed by business partner Strand Life Science and MediBIC.
Mar. 2006	Establishment of MediBIC Pharma (Subsidiary of MediBIC Group) .

Nov. 2005	MediBIC appointed as the commercialization and business partner for the Foundation of Translational Research Informatics (TRI) Center for specimen banking services.
Sep. 2005	MediBIC and Kazusa DNA Research Institute start co-development program to provide support services such as new drug development.
Jun. 2005	Launch of investment banking operation of MediBIC Alliance.
May 2005	Establishment of Shanghai Office.
Apr. 2005	MediBIC and ReaMetrix (US / India) start business collaboration, co-development and sales of new solutions on cellular function analysis.
Mar. 2005	Joint establishment of investment fund by MediBIC Alliance and Daiichi Pharmaceutical, aimed at investing in early to mid-stage US and European biotech companies with specific technology profiles.
Feb. 2005	MediBIC collaborates with NuGEN technologies. Starts sales and technical support for RNA amplification system in Asia

Dec. 2004	MediBIC and Threshold Pharmaceuticals agree to co-develop Glufosfamide (anti-cancer drug ) in Asia
Dec. 2004	MediBIC starts protein engineering services collaboration with DNA 2.0
Dec. 2004	MediBIC is recognized as the 20th fastest growing company in the Deloitte and Touche’s Fast500 Asia Award
Sep. 2004	MediBIC receives No.1 Award in the Deloitte and Touche’s Top 50 Fastest Growing Technology Companies
Sep. 2004	MediBIC launches Proteome Analysis Service for drug development.
Aug. 2004	Two-for-One Stock Split of MediBIC Stocks
Aug. 2004	MediBIC and NS Solutions start co-development of chronic disease gene analysis software.
Aug. 2004	MediBIC and Strand Genomics (India, Currently Strand Life Sciences, Pvt. Ltd) start business partnership on co-development and support services.
Jul. 2004	MediBIC and CrystalGenomics (Korean Bioventure) Inc. start business partnership on operation and R&D
Mar. 2004	MediBIC and Lymphotec reaches agreement on co-developing new technologies for immune cell therapy by utilizing genomic information
Mar. 2004	Establishment of MediBIC Alliance (subsidiary of MediBIC)
Feb. 2004	Dr. Yasuhiro Hashimoto (President & CEO) receives "Minister's award" in entrepreneurship by Ministry of Economy, Trade and Industry
Jan. 2004	Establishment of "Anexus Pharmaceuticals, Inc" (US subsidiary)

Sep. 2003	MediBIC goes public on the Tokyo Stock Exchange (Mothers Board). The total capital achieved: 1,075 Million Yen
May. 2003	MediBIC and SurroMed (USA, Currently PPD Inc.) starts operation and R&D affiliation

Jun. 2002	MediBIC and Shin Nittetsu Solutions Co., Ltd agrees to establish a cooperative structure for medical product R&D
Apr. 2002	Establishment of Kansai Branch (currently Kansai Laboratory) in Kobe
Jan. 2002	MediBIC develops an informatics system that analyses genetic correlations, enabling MediBIC to advance into the bioinformatics market

Nov. 2000	MediBank changes its name to MediBIC.
Feb. 2000	Founded as MediBank (10 Million Yen in Capital) in Shinagawa as consulting business targeting major pharmaceutical companies.